NeuroOne Medical Technologies Corporation

Product revenue in the third quarter of fiscal 2026 was $2.0 million, up 16% year over year from $1.7 million. Product gross profit was $1.2 million, or 59.9% of product revenue, versus $0.9 million, or 53.9%, a year ago. New product orders were $2.7 million, up 43% year over year, with backlog at $1.7 million as of June 30, 2026. Net loss was $2.0 million, or $0.23 per basic share and $0.28 per diluted share, versus a net loss of $1.5 million, or $0.19 per basic share and $0.22 per diluted share last year. For fiscal 2026, management expects product orders of approximately $11.2 million and recognized revenue between $9.2 million and $10.5 million, depending on shipment timing.

Dave Rosa framed the quarter as a mix of commercial progress and platform expansion. He highlighted the 16% revenue increase, margin expansion, ISO 13485 certification, and the lead investor increasing holdings from 7.4% to 12.5% after quarter end. He also emphasized that NeuroOne is pushing into international markets, Trigeminal commercialization, drug delivery, and BVNA, while stressing that the company must balance growth with manufacturing execution and cost discipline.

Chris Volker said product revenue was $2.0 million and orders were $2.7 million, with orders exceeding recognized revenue and backlog at $1.7 million. He noted product gross profit of $1.2 million, or 59.9%, and said the margin improvement came from a more favorable sales mix toward higher-margin products. Operating expenses were $3.6 million, including R&D of $1.4 million and SG&A of $2.2 million, and net loss was $2.0 million, helped by a $0.4 million gain from the warrant liability revaluation. Cash and cash equivalents were $2.0 million, working capital was $3.7 million, the company had $1.1 million in receivables expected to convert to cash in Q4, and it raised $0.4 million via ATM in the quarter plus another $1.0 million after quarter end; no debt was outstanding.

Analysts focused on the University of Minnesota epilepsy study, manufacturing backlog, international expansion, StereoCED’s commercial path, and Trigeminal commercialization. Management said the Minnesota work is for focal epilepsy and preclinical testing is expected in the next quarter before any potential Phase I. On backlog, Rosa said lead times can be as long as six months and the second manufacturing site is expected in the first part of 2027; on ex-U.S. markets, he said ISO 13485 is the key credential and that Zimmer and NeuroOne are assessing territories, with more clarity expected next quarter. Rosa also said Zimmer remains interested in Trigeminal, but Brain Ablation backlog has been prioritized, and he said the revenue guide range reflects manufacturing constraints rather than demand.